Clinical Trial Update: Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC [Phase 2]

View source ↗

Summary

Phase 2 trial updating ablation plus tislelizumab versus ablation alone for intrahepatic recurrent early-stage hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Ming Zhao | Conditions: Recurrent Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN